1. Test-retest reliability of pain VAS/NRS, stiffness VAS/NRS, HAQ-DI and mHAQ in polymyalgia rheumatica: An OMERACT study.
- Author
-
Leung JL, Twohig H, Muller S, Maxwell L, Mackie SL, Neill LM, and Owen CE
- Subjects
- Humans, Reproducibility of Results, Pain, Surveys and Questionnaires, Polymyalgia Rheumatica diagnosis, Giant Cell Arteritis
- Abstract
Objective: To examine the test-retest reliability of four measurement instruments in polymyalgia rheumatica (PMR): pain severity visual analogue scale (VAS) / numerical rating score (NRS), stiffness severity VAS/NRS, the Health Assessment Questionnaire-Disability Index (HAQ-DI) and the modified Health Assessment Questionnaire (mHAQ)., Method: Two prospectively collected datasets were used. All participants had a diagnosis of PMR and only those with stable disease were included in analyses. Measurement instruments were administered twice, with a testing interval of two to six weeks. The intra-class correlation coefficient (ICC) was calculated using a two-way mixed effects model looking for absolute agreement. ICC values of 0.8-0.9 were deemed representative of good test-retest reliability, whilst values >0.9 were representative of excellent test-retest reliability., Results: From the first dataset, 38 participants were analysed. The ICC between baseline and 2 weeks for pain VAS, stiffness VAS, HAQ-DI and mHAQ were 0.84, 0.82, 0.92 and 0.92 respectively. From the second dataset, 58 participants were included in the analysis for pain NRS, 59 for stiffness NRS and 78 for mHAQ. The ICC between baseline and follow-up for pain NRS, stiffness NRS and mHAQ were 0.80, 0.83 and 0.87 respectively., Conclusion: Pain severity VAS/NRS, stiffness severity VAS/NRS, HAQ-DI and mHAQ all demonstrate good to excellent test-retest reliability in a PMR patient population., Competing Interests: Declaration of Competing Interest Jessica L. Leung has received speaker honoraria from Novartis, Eli Lilly and AbbVie, as well as payment for advisory board participation from Fresenius Kabi, Eli Lilly and AbbVie. Helen Twohig has no declarations of interest. Sara Muller is a trustee of the PMRGCAuk charity. Lara Maxwell has no declarations of interest. Sarah L. Mackie's institution has received grant funding from the National Institute for Health Research, Leeds Hospitals Charity and Vifor Pharmaceuticals, and payment for clinical trial participation from Sanofi. She has received support for virtual attendance at ACR Convergence 2021. She is also the patron of the PMRGCAuk charity (unpaid role) and is supported in part by the NIHR Leeds Bioedical Research Centre. Lorna M. Neill has received honoraria from AbbVie and is a trustee of PMR-GCA Scotland Charity. Claire E. Owen has received speaking honoraria from AbbVie and Novartis, as well as payment for advisory board participation from AbbVie., (Copyright © 2023. Published by Elsevier Inc.)
- Published
- 2023
- Full Text
- View/download PDF